Genetic ablation of LIFR and pharmacologic LIF blockade in the KPC mouse model demonstrated that LIF mainly acts on pancreatic cancer cells to facilitate tumor progression but not initiation. The gene discussed is LIF; the disease is pancreatic neoplasm.